The financial results revealed a net loss of $20.2 million for the fourth quarter and $219 million for the full year, compared to a net loss of $51.9 million and $169 million for the same periods in 2024, respectively. The decrease in cash and cash equivalents to $628.1 million as of December 31, 2025, from $879.5 million a year earlier, was attributed to increased operational expenses, particularly in clinical program activities. Collaboration revenue surged to $48 million for the fourth quarter, up from $3.7 million in the previous year, primarily due to the recognition of revenue from terminated collaborations with Novartis and Bayer.
Bicycle Therapeutics also announced a strategic reprioritization of its pipeline, focusing on next-generation therapeutics, including BT5528 and Bicycle Radioconjugates. The company plans to convert its ongoing Duravelo-2 trial for zelenectide into a randomized Phase 2 study while deprioritizing the program for internal development. This strategic shift is expected to extend the company's cash runway into 2030, with a proposed workforce reduction of approximately 30% aimed at achieving operational savings of about 50% annually.
The leadership transition and financial results reflect Bicycle Therapeutics' commitment to optimizing its resources and focusing on promising therapeutic candidates. The company aims to leverage its proprietary bicyclic peptide technology to develop innovative treatments for oncology and other diseases, positioning itself for future growth in a competitive market.
